All In Biotech

Drug Trial Radar · NCT05020236

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR

Last checked: Nov 20, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 893 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

893

Planned (sponsor's estimate)

Start

Oct 4, 2021

Primary completion

Feb 26, 2026

Study completion May 31, 2027

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Aug 25, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone, and (2) learn about the safety and activity of elranatamab in combination with the anti-CD38 monoclonal antibody daratumumab. People with multiple myeloma who have received previous treatment including lenalidomide will be enrolled in the study. Part 1 of the study will assess the safety and activity of different doses of elranatamab in combination with daratumumab. People participating in Part 2 of the study will be randomly assigned to receive either elranatamab alone, elranatamab plus daratumumab, or daratumumab, pomalidomide, and dexamethasone. Part 2 will evaluate the safety and activity of (1) elranatamab alone compared to daratumumab, pomalidomide, and dexamethasone, and (2) elranatamab plus daratumumab. Part 3 will assess the effect of increased measures to protect against infection in people treated with either elranatamab alone or together with daratumumab. All people participating in the study will receive study treatment until their disease progresses, they experience unacceptable side effects, or they choose to no longer participate in the study.

Conditions

  • Multiple Myeloma

Interventions

  • ElranatamabDrug

    subcutaneous

  • DaratumumabDrug

    Daratumumab / hyaluronidase, subcutaneous

  • PomalidomideDrug

    oral

  • DexamethasoneDrug

    oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 Safety Lead-In: Incidence of dose limiting toxicitiesTime frame: First 42 days after first elranatamab dose
  2. Part 2 Randomized: Progression free survival per International Myeloma Working Group criteriaTime frame: From date of randomization to date of progressive disease, discontinuation from the study, death, or censoring, whichever occurs first, assessed up to 51 months
  3. Part 3: Frequency of treatment-emergent adverse eventsTime frame: First 84 days after first elranatamab dose

Locations

237 sites in 26 countries. Site status is shown where the registry gives one.

  • Clovis Community Medical Center

    Clovis, California · Active not recruiting

  • Community Cancer Institute

    Clovis, California · Active not recruiting

  • University of California San Francisco

    Fresno, California · Active not recruiting

  • Community Regional Medical Center

    Fresno, California · Active not recruiting

  • UCHealth Poudre Valley Hospital

    Fort Collins, Colorado · Active not recruiting

  • UCHealth Harmony

    Fort Collins, Colorado · Active not recruiting

  • UCHealth Greeley Hospital

    Greeley, Colorado · Active not recruiting

  • UCHealth - Medical Center of the Rockies

    Loveland, Colorado · Active not recruiting

  • Sylvester Comprehensive Cancer Center - Aventura

    Aventura, Florida · Recruiting

  • Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center

    Coral Gables, Florida · Recruiting

  • Sylvester Comprehensive Cancer Center - Coral Springs

    Coral Springs, Florida · Recruiting

  • University of Miami Hospital and Clinics - Deerfield Beach

    Deerfield Beach, Florida · Recruiting

  • Sylvester Comprehensive Cancer Center - Hollywood

    Hollywood, Florida · Recruiting

  • Sylvester Comprehensive Cancer Center

    Miami, Florida · Recruiting

  • University of Miami Hospital and Clinics

    Miami, Florida · Recruiting

  • Sylvester Comprehensive Cancer Center - Kendall

    Miami, Florida · Recruiting

  • Sylvester Comprehensive Cancer Center - Plantation

    Plantation, Florida · Recruiting

  • East Jefferson General Hospital

    Metairie, Louisiana · Active not recruiting

  • MSK Basking Ridge

    Basking Ridge, New Jersey · Recruiting

  • MSK Monmouth

    Middletown, New Jersey · Recruiting

  • MSK Bergen

    Montvale, New Jersey · Recruiting

  • MSK Commack

    Commack, New York · Recruiting

  • MSK Westchester

    Harrison, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center - Main Campus

    New York, New York · Recruiting

  • MSK Nassau

    Uniondale, New York · Recruiting

  • Alexander Fleming S.A (Instituto Medico Especializado Alexander Fleming)

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Terminated

  • FUNDALEU - Fundacion para combatir la Leucemia

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Recruiting

  • FUNDALEU -Fundación para combatir la leucemia

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting

  • FUNDALEU

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Hospital Italiano de La Plata

    La Plata, Buenos Aires, Argentina · Active not recruiting

  • Hospital Universitario Austral

    Presidente Derqui, Buenos Aires, Argentina · Active not recruiting

  • Sanatorio de La Mujer

    Rosario, Santa Fe Province, Argentina · Active not recruiting

  • Pindara Private Hospital

    Benowa, Queensland, Australia · Recruiting

  • QScan Radiology Clinics

    Clayfield, Queensland, Australia · Recruiting

  • Gallipoli Medical Research Foundation

    Greenslopes, Queensland, Australia · Active not recruiting

  • Greenslopes Private Hospital

    Greenslopes, Queensland, Australia · Active not recruiting

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia · Recruiting

  • Epworth Freemasons

    East Melbourne, Victoria, Australia · Recruiting

  • St Vincent's Hospital (Melbourne)

    Fitzroy, Victoria, Australia · Recruiting

Showing 40 of 237 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.